Since Novel-3 is non-coding and unable to produce a protein (Table 1), its increased expression could lower functional APOC3 levels, providing a potential therapeutic strategy for conditions like hypertriglyceridemia, where reducing APOC3 expression has been shown to be advantageous [42]. Here, APOC3 is linked to hypertriglyceridemia.